HYPERCAPNIA
Phase 2Biologic
HYPERCAPNIA is one of 30 biologic programs targeting Ischemic stroke. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
29
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
430 competitors in Ischemic Stroke
#DrugCompanyPhaseTrials
1Repatha
AmgenPreclinical
Proamatine
TakedaPreclinical
Levaquin
WWim Janssens
Preclinical
Tylenol
KKenvue Brands
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Xylocaine
CCitius Pharmaceuticals, Inc.
Preclinical
Statins
SanofiPreclinical
HYPERCAPNIA
UUniversity Hospital, Clermont-Ferrand
Phase 2
Urokinase
Mmedac GmbH
Preclinical
Drug Therapy
MMassachusetts General Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HYPERCAPNIA. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details